
REPL Stock Forecast & Price Target
REPL Analyst Ratings
Bulls say
Replimune Group's outlook is bolstered by a significant increase in the probability of approval for its lead candidate, RP1 in combination with Opdivo, which has been raised to 85%, demonstrating strong confidence in its clinical potential. The safety profile of RP1 + Opdivo is favorable, with a reported 12.8% incidence of grade 3 or higher treatment-related adverse events, indicating a manageable risk for patients. The positive results from the IGNYTE trial further support the case for approval, positioning Replimune favorably in the competitive landscape of cancer therapeutics.
Bears say
Replimune Group Inc faces significant challenges in advancing its key product candidate, RP1, due to regulatory and clinical trial setbacks, including the FDA's determination that the IGNYTE trial lacked adequate evidence of effectiveness. Additionally, the company must contend with risks related to its inability to generate compelling efficacy and safety data, potential dilution, and the failure to deliver on the expectations of its early-stage pipeline of oncolytic virus candidates. The complexity and heterogeneity of the patient population, along with inadequate trial design and statistical assumptions, further hinder Replimune's prospects for regulatory approval, contributing to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.
REPL Analyst Forecast & Price Prediction
Start investing in REPL
Order type
Buy in
Order amount
Est. shares
0 shares